Capacity of type I and II ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif-Relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells

Biochemical Pharmacology

Volumn 79, Issue 5, 2010, Pages 746-757

  Bourgoin Voillard, Sandrine ^a,b   Gallo, Dominique ^a   Laïos, Ioanna ^a   Cleeren, Anny ^a   Bali, Latifa El ^a   Jacquot, Yves ^b   Nonclercq, Denis ^c   Laurent, Guy ^c   Tabet, Jean Claude ^b   Leclercq, Guy ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF MONS   (Belgium)

Author keywords

Downregulation; Estrogen receptor alpha; Ligands; LxxLL motif; Transcriptional activity

Indexed keywords

COUMESTROL; DIETHYLSTILBESTROL; ESTRADIOL DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GENISTEIN; IMIDAZOLINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CELL STRAIN MCF 7; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN MOTIF; RECEPTOR DOWN REGULATION; TRANSACTIVATION;

EID: 71849084143     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.10.015     Document Type: Article

References (47)

1. Tsai M.J., and O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63 (1994) 451-486
2. McGuire W.L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5 (1978) 428-433
3. Jordan V.C., Schafer J.M., Levenson A.S., Liu H., Pease K.M., Simons L.A., et al. Molecular classification of estrogens. Cancer Res 61 (2001) 6619-6623
4. Lubczyk V., Bachmann H., and Gust R. Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes. J Med Chem 45 (2002) 5358-5364
5. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
6. Kekenes-Huskey P.M., Muegge I., von R.M., Gust R., and Knapp E.W. A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores. Bioorg Med Chem 12 (2004) 6527-6537
7. Bai Z., and Gust R. Breast cancer, estrogen receptor and ligands. Arch Pharm (Weinheim) 342 (2009) 133-149
8. Anstead G.M., Carlson K.E., and Katzenellenbogen J.A. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62 (1997) 268-303
9. Heery D.M., Kalkhoven E., Hoare S., and Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 (1997) 733-736
10. Iannone M.A., Simmons C.A., Kadwell S.H., Svoboda D.L., Vanderwall D.E., Deng S.J., et al. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol Endocrinol 18 (2004) 1064-1081
11. Ozers M.S., Ervin K.M., Steffen C.L., Fronczak J.A., Lebakken C.S., Carnahan K.A., et al. Analysis of ligand-dependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization. Mol Endocrinol 19 (2005) 25-34
12. Savkur R.S., and Burris T.P. The coactivator LXXLL nuclear receptor recognition motif. J Pept Res 63 (2004) 207-212
13. Tamrazi A., Carlson K.E., Rodriguez A.L., and Katzenellenbogen J.A. Coactivator proteins as determinants of estrogen receptor structure and function: spectroscopic evidence for a novel coactivator-stabilized receptor conformation. Mol Endocrinol 19 (2005) 1516-1528
14. Klinge C.M. Estrogen receptor interaction with co-activators and co-repressors. Steroids 65 (2000) 227-251
15. McKenna N.J., Lanz R.B., and O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20 (1999) 321-344
16. Rosenfeld M.G., Lunyak V.V., and Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 20 (2006) 1405-1428
17. Laios I., Journe F., Nonclercq D., Vidal D.S., Toillon R.A., Laurent G., et al. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J Steroid Biochem Mol Biol 94 (2005) 347-359
18. Lonard D.M., Nawaz Z., Smith C.L., and O'Malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 5 (2000) 939-948
19. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11 (2003) 695-707
20. Gallo D., Jacquot Y., Cleeren A., Jacquemotte F., Laios I., Laurent G., et al. Molecular basis of agonistic activity of ER alpha 7p, a synthetic peptide corresponding to a sequence located at the N-terminal part of the estrogen receptor alpha ligand binding domain. Lett Drug Design Discov 4 (2007) 346-355
21. von R.M., Schlenk M., and Gust R. Effects of C2-alkylation, N-alkylation, and N,N′-dialkylation on the stability and estrogen receptor interaction of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines. J Med Chem 47 (2004) 915-927
22. Agouridas V., Blazejewski J.C., Cleeren A., Laios I., Leclercq G., and Magnier E. Fluorous tolerance of the estrogen receptor alpha as probed by 11-polyfluoroalkylestradiol derivatives. Steroids 73 (2008) 320-327
23. Maaroufi Y., and Leclercq G. Importance of A/B and C domains of the estrogen receptor for its adsorption to hydroxylapatite. J Steroid Biochem Mol Biol 48 (1994) 155-163
24. Pons M., Gagne D., Nicolas J.C., and Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 9 (1990) 450-459
25. Stoessel S., and Leclercq G. Competitive binding assay for estrogen receptor in monolayer culture: measure of receptor activation potency. J Steroid Biochem 25 (1986) 677-682
26. Jacquot Y., Laios I., Cleeren A., Nonclercq D., Bermont L., Refouvelet B., et al. Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells. Bioorg Med Chem 15 (2007) 2269-2282
27. Celik L., Lund J.D., and Schiott B. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics. Biochemistry 46 (2007) 1743-1758
28. (11) position on gas phase acidity. J Am Soc Mass Spectrom (2009) 10.1016/j.jasms.2009.08.017
29. Laios I., Cleeren A., Leclercq G., Nonclercq D., Laurent G., Schlenk M., et al. Effects of (R,S)/(S,R)-4,5-bis(2-chloro-4-hydroxyphenyl)-2-imidazolines and (R,S)/(S,R)-2,3-bis(2-chloro-4-hydroxyphenyl)piperazines on estrogen receptor alpha level and transcriptional activity in MCF-7 cells. Biochem Pharmacol 74 (2007) 1029-1038
30. Alarid E.T. Lives and times of nuclear receptors. Mol Endocrinol 20 (2006) 1972-1981
31. Leclercq G., Lacroix M., Laios I., and Laurent G. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr Cancer Drug Targets 6 (2006) 39-64
32. Legros N., Leclercq G., and McCague R. Effect of estrogenic and antiestrogenic triphenylethylene derivatives on progesterone and estrogen receptors levels of MCF-7 cells. Biochem Pharmacol 42 (1991) 1837-1841
33. El Khissiin A., Cleeren A., Borras M., and Leclercq G. Protein synthesis is not implicated in the ligand-dependent activation of the estrogen receptor in MCF-7 cells. J Steroid Biochem Mol Biol 62 (1997) 269-276
34. El Khissiin A., and Leclercq G. Implication of proteasome in estrogen receptor degradation. FEBS Lett 448 (1999) 160-166
35. Marsaud V., Gougelet A., Maillard S., and Renoir J.M. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol Endocrinol 17 (2003) 2013-2027
36. Agouridas V., Magnier E., Blazejewski J.C., Laios I., Cleeren A., Nonclercq D., et al. Effect of fluorination on the pharmacological profile of 11beta isomers of fulvestrant in breast carcinoma cells. J Med Chem 52 (2009) 883-887
37. Tedesco R., Katzenellenbogen J.A., and Napolitano E. 7 Alpha,11 beta-disubstituted estrogens: probes for the shape of the ligand binding pocket in the estrogen receptor. Bioorg Med Chem Lett 7 (1997) 2919-2924
38. Seo J.W., Comninos J.S., Chi D.Y., Kim D.W., Carlson K.E., and Katzenellenbogen J.A. Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem 49 (2006) 2496-2511
39. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
40. Fowler A.M., and Alarid E.T. Dynamic control of nuclear receptor transcription. Sci STKE (2004) e51
41. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
42. Hammes S.R., and Levin E.R. Extranuclear steroid receptors: nature and actions. Endocr Rev 28 (2007) 726-741
43. Kampa M., Pelekanou V., and Castanas E. Membrane-initiated steroid action in breast and prostate cancer. Steroids 73 (2008) 953-960
44. Seo H.S., and Leclercq G. Evaluation of potential implication of membrane estrogen binding sites on ERE-dependent transcriptional activity and intracellular estrogen receptor-alpha regulation in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 80 (2002) 109-123
45. Taguchi Y., Koslowski M., and Bodenner D.L. Binding of estrogen receptor with estrogen conjugated to bovine serum albumin (BSA). Nucl Recept 2 (2004) 5
46. Wessler S., Otto C., Wilck N., Stangl V., and Fritzemeier K.H. Identification of estrogen receptor ligands leading to activation of non-genomic signaling pathways while exhibiting only weak transcriptional activity. J Steroid Biochem Mol Biol 98 (2006) 25-35
47. Harrington W.R., Kim S.H., Funk C.C., Madak-Erdogan Z., Schiff R., Katzenellenbogen J.A., et al. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 20 (2006) 491-502